Completion and commencement of operations at the Second Formulation Building of the Ibaraki Plant
First written in FY2016. 6 of 9 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AchievedAnnual report
「The expansion work has now been completed, and operations began on 22 January 2024.」
The expansion work to add a new line to the powdered dialysis agent production facilities for artificial kidneys at the second formulation building of the Ibaraki Plant was completed, and operations began on 22 January 2024. - FY2023AdvancedAnnual report
「During the fiscal year, the company raised funds under this policy to invest in adding a new line to the powdered dialysis agent production facilities at the second formulation building of the Ibaraki Plant, as well as for research and development activities.」
The company invested in adding a new line to the powdered dialysis agent production facilities at the existing second formulation building of the Ibaraki Plant. - FY2022RestatedAnnual report
「April 2016: Second formulation building established at the Ibaraki Plant (Kitaibaraki, Ibaraki Prefecture)」
The company reconfirmed in its corporate history that the second formulation building at the Ibaraki Plant had been established. - FY2021RestatedAnnual report
「April 2016: Second formulation building established at the Ibaraki Plant (Kitaibaraki, Ibaraki Prefecture)」
The company reconfirmed in its corporate history that the second formulation building at the Ibaraki Plant had been established. - FY2019RestatedAnnual report
「April 2016: Second formulation building established at the Ibaraki Plant (Kitaibaraki, Ibaraki Prefecture)」
The company reconfirmed in its corporate history that the second formulation building at the Ibaraki Plant had been established. - FY2018RestatedAnnual report
「April 2016: Second formulation building established at the Ibaraki Plant (Kitaibaraki, Ibaraki Prefecture)」
The company reconfirmed in its corporate history that the second formulation building at the Ibaraki Plant had been established. - FY2017RestatedAnnual report
「The second formulation building at the Ibaraki Plant, a production facility for powdered dialysis agents, was completed and began operations in April 2016, further strengthening the company’s ability to ensure a stable supply of Kindaly dialysis agents, including in the event of a disaster.」
The company reconfirmed the completion and commencement of operations of the second formulation building in April 2016 and the strengthening of its stable supply system. - FY2017-Q1RestatedAnnual report
「In production, the completion and commencement of operations in April 2016 of the second formulation building added at the Ibaraki Plant strengthened the company’s ability to ensure a more stable supply of Kindaly dialysis agents for artificial kidneys, including in the event of a disaster.」
The company reconfirmed the completion and commencement of operations of the second formulation building at the Ibaraki Plant in April 2016 and the strengthening of its stable supply system. - FY2016First statedAnnual report
「The company had been carrying out construction of a second formulation building at the Ibaraki Plant as a production facility for powdered dialysis agents. With the building completed and becoming operational in April 2016, the company strengthened its ability to ensure a more stable supply of Kindaly dialysis agents, including in the event of a disaster.」
The company reported the specific facility milestone of completing and commencing operations of the powdered dialysis agent production facility in April 2016.